Rgenta Therapeutics Unveils Promising Data on RGT-61159 Inhibitor at EHA 2025 Congress#USA#Rgenta_Therapeutics#Woburn#RGT-61159#MYB_RNA
Rgenta Therapeutics Unveils Promising Data on RGT-61159 Inhibitor at EHA 2025 Congress
Rgenta Therapeutics will present preclinical findings on its innovative MYB RNA inhibitor, RGT-61159, at EHA 2025 in Milan, showcasing significant anti-tumor activity.
third-news.com
May 14, 2025 at 2:34 PM
Rgenta Therapeutics Unveils Promising Data on RGT-61159 Inhibitor at EHA 2025 Congress#USA#Rgenta_Therapeutics#Woburn#RGT-61159#MYB_RNA
Rgenta Therapeutics Unveils Promising RSwitch Technology for Gene Therapy Regulation#USA#gene_therapy#Rgenta_Therapeutics#Woburn#RSwitch_technology
Rgenta Therapeutics Unveils Promising RSwitch Technology for Gene Therapy Regulation
Rgenta Therapeutics showcased their RSwitch technology at the ASGCT 2025 Annual Meeting. This innovation allows precise control of gene expression in therapies, promising significant advancements in treating complex diseases.
third-news.com
May 13, 2025 at 9:13 PM
Rgenta Therapeutics Unveils Promising RSwitch Technology for Gene Therapy Regulation#USA#gene_therapy#Rgenta_Therapeutics#Woburn#RSwitch_technology
Innovative Oral Small Molecule RGT-61159 Shows Promise Against AML#USA#AML#Rgenta_Therapeutics#RGT-61159#Woburn,_MA
Innovative Oral Small Molecule RGT-61159 Shows Promise Against AML
Rgenta Therapeutics has unveiled preclinical data indicating that their oral MYB inhibitor, RGT-61159, exhibits strong anti-tumor effects in AML models and synergizes effectively with standard treatments.
third-news.com
April 25, 2025 at 5:11 PM
Innovative Oral Small Molecule RGT-61159 Shows Promise Against AML#USA#AML#Rgenta_Therapeutics#RGT-61159#Woburn,_MA
Rgenta Therapeutics Showcases Promising Anti-Cancer Drug RGT-61159 at ASH Annual Meeting#United_States#San_Diego#AML#Rgenta_Therapeutics#RGT-61159
Rgenta Therapeutics Showcases Promising Anti-Cancer Drug RGT-61159 at ASH Annual Meeting
Rgenta Therapeutics presents groundbreaking preclinical data on RGT-61159, a novel MYB inhibitor, at the ASH Annual Meeting, promising new avenues for AML treatment.
third-news.com
December 9, 2024 at 5:08 PM
Rgenta Therapeutics Showcases Promising Anti-Cancer Drug RGT-61159 at ASH Annual Meeting#United_States#San_Diego#AML#Rgenta_Therapeutics#RGT-61159
Rgenta Therapeutics Enters Strategic Collaboration with GSK for RNA-Targeted Therapies#United_States#GSK#Rgenta_Therapeutics#RNA-Targeted_Therapies#Woburn
Rgenta Therapeutics Enters Strategic Collaboration with GSK for RNA-Targeted Therapies
Rgenta Therapeutics and GSK form a strategic alliance to develop novel RNA-targeted small molecule splice modulators for various diseases.
third-news.com
December 4, 2024 at 1:25 PM
Rgenta Therapeutics Enters Strategic Collaboration with GSK for RNA-Targeted Therapies#United_States#GSK#Rgenta_Therapeutics#RNA-Targeted_Therapies#Woburn